On June 17th, Gelunhui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) and its subsidiary Shandong Shengdi Pharmaceuticals Co., Ltd. received approval from the National Medical Products Administration for the clinical trial of HRS7415 tablets and HRS-8080 tablets and will conduct the trial soon. HRS7415 tablets inhibit the phosphorylation of substrate proteins by inhibiting AKT, regulate downstream signaling pathways, thereby inhibiting cell proliferation and exhibiting anticancer effects. HRS-8080 is a novel, efficient, and selective oral estrogen receptor (ER) degrader. It can degrade ER powerfully and selectively, suppress ER activity and downstream signaling, thereby inhibiting the proliferation of tumor cells. It is intended to treat ER-positive and ER-mutated breast cancer.
恒瑞医药(600276.SH)：HRS7415片、HRS-8080片获得药物临床试验批准通知书
Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS7415 tablets, HRS-8080 tablets have obtained the notice of drug clinical trial approval.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.